Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

@article{Kluger2014SurvivalRD,
  title={Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).},
  author={Harriet M. Kluger and Margaret K. Callahan and Michael A Postow and Ruth Ann Gordon and Neil Howard Segal and Naiyer A Rizvi and Alexander M Lesokhin and Michael B. Atkins and John Munn Kirkwood and Matthew M. Burke and Amanda L Ralabate and Angel L Rivera and Stephanie Anne Kronenberg and Blessing U Agunwamba and William Feely and Quan Hong and Suba Krishnan and Ashok Gupta and Jedd D Wolchok},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 18_suppl},
  pages={LBA9003}
}
LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I trial of concurrent and sequenced NIVO + IPI. METHODS MEL pts (n=53, enrolled 2009-2012, data analysis Dec 2013) with ≤3 prior therapies received IV concurrent NIVO + IPI, Q3Wk × 4 doses, followed by NIVO Q3Wk × 4. At wk 24, NIVO + IPI continued Q12Wk × 8 in pts with disease control and no DLT. Tumor responses were evaluated by WHO and immune-related… CONTINUE READING

From This Paper

Topics from this paper.
75 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

Similar Papers

Loading similar papers…